Shopping Cart
Remove All
Your shopping cart is currently empty
Grisnilimab (WT1) is a monoclonal antibody targeting CD7. CD7 plays a crucial role in T cell and T cell/B cell interactions, and the Wilms' tumour 1 (WT1) gene is overexpressed in leukaemia and various types of solid tumours (such as lung cancer and colorectal cancer).
| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $332 | - | In Stock | |
| 5 mg | $996 | - | In Stock | |
| 10 mg | $1,570 | - | In Stock | |
| 25 mg | $2,330 | - | In Stock | |
| 50 mg | $3,130 | - | In Stock |
| Description | Grisnilimab (WT1) is a monoclonal antibody targeting CD7. CD7 plays a crucial role in T cell and T cell/B cell interactions, and the Wilms' tumour 1 (WT1) gene is overexpressed in leukaemia and various types of solid tumours (such as lung cancer and colorectal cancer). |
| Synonyms | WT1, WT 1 |
| Reactivity | Human |
| Application | FACS Functional assay |
| Antibody Type | Monoclonal |
| Host Species | < 1.0 EU/mg |
| Conjucates | Unconjugated |
| Uniprot ID |
| Cas No. | 2367001-70-3 |
| Storage | store at low temperature | -20°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. |
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2025 TargetMol Chemicals Inc. All Rights Reserved.